Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
US Army
Fish and Richardson
McKesson
Merck
Daiichi Sankyo
QuintilesIMS
Citi
Farmers Insurance

Generated: February 23, 2018

DrugPatentWatch Database Preview

RENORMAX Drug Profile

« Back to Dashboard

When do Renormax patents expire, and when can generic versions of Renormax launch?

Renormax is a drug marketed by Schering and is included in one NDA.

The generic ingredient in RENORMAX is spirapril hydrochloride. Additional details are available on the spirapril hydrochloride profile page.
Summary for RENORMAX
Drug patent expirations by year for RENORMAX

US Patents and Regulatory Information for RENORMAX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-001 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-004 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-002 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-003 Dec 29, 1994 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for RENORMAX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-001 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-004 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-002 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Schering RENORMAX spirapril hydrochloride TABLET;ORAL 020240-003 Dec 29, 1994 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Chinese Patent Office
Mallinckrodt
QuintilesIMS
Queensland Health
Fish and Richardson
US Army
Covington
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot